The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy | Haematologica
A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys | Scientific Reports
Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning | Scientific Reports
Immunohistochemical staining for Syk in reactive and neoplastic T... | Download Scientific Diagram
Characterization of the canine CD20 as a therapeutic target for comparative passive immunotherapy | Scientific Reports
Flow cytometric classification of CD20 levels. a Negative, no... | Download Scientific Diagram
DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing - eBioMedicine
Cells | Free Full-Text | Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients
Detection of subsets of CD3+CD20+ T cells in healthy subjects. (A) (i)... | Download Scientific Diagram
Loss of CD20 results in altered expression of B cell surface markers... | Download Scientific Diagram
Flow cytometry of PBMCs sorted by alternative gating for CD32hi,... | Download Scientific Diagram
Animals | Free Full-Text | Co-Expression of T- and B-Cell Markers in a Canine Intestinal Lymphoma: A Case Report
Anti-CD20/CD3 TDB is potent in killing human lymphoma B cell lines and... | Download Scientific Diagram
Cancers | Free Full-Text | Immunotherapy for Diffuse Large B-Cell Lymphoma: Current Landscape and Future Directions
Antibody drug development: Targeting CD20 and CD3
A, B Lymphocyte markers (CD3 and CD20) on the skin of individuals... | Download Scientific Diagram
Frontiers | Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?
Targeting CD20 and CD3, the witness and creator in the process of antibody drug development - ACROBiosystems
Diagnostics | Free Full-Text | Rituximab Plus Chemotherapy Provides No Clinical Benefit in a Peripheral T-Cell Lymphoma not Otherwise Specified with Aberrant Expression of CD20 and CD79a: A Case Report and Review
B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome | Nature Reviews Clinical Oncology
Immunohistochemical staining for mono nuclear cell infiltration,... | Download Scientific Diagram
APC/CY7 Anti-Human CD20, B-Ly1 | SouthernBiotech
Detection of subsets of CD3+CD20+ T cells in healthy subjects. (A) (i)... | Download Scientific Diagram
CD20 expression and localization on WT Ramos B cells. (A) Flow... | Download Scientific Diagram
